| Literature DB >> 31307479 |
Babak Haghighi1,2, Sanghun Choi3, Jiwoong Choi1,2, Eric A Hoffman4,5,6, Alejandro P Comellas6, John D Newell4, Chang Hyun Lee4,7, R Graham Barr8, Eugene Bleecker9, Christopher B Cooper10, David Couper11, Mei Lan Han12, Nadia N Hansel13, Richard E Kanner14, Ella A Kazerooni15, Eric A C Kleerup16, Fernando J Martinez17, Wanda O'Neal18, Robert Paine14, Stephen I Rennard19,20, Benjamin M Smith21,22, Prescott G Woodruff23, Ching-Long Lin24,25,26,27,28.
Abstract
BACKGROUND: Quantitative computed tomographic (QCT) imaging-based metrics enable to quantify smoking induced disease alterations and to identify imaging-based clusters for current smokers. We aimed to derive clinically meaningful sub-groups of former smokers using dimensional reduction and clustering methods to develop a new way of COPD phenotyping.Entities:
Keywords: COPD; Emphysema; Former smokers; Functional small airway disease; Imaging-based cluster analysis
Mesh:
Year: 2019 PMID: 31307479 PMCID: PMC6631615 DOI: 10.1186/s12931-019-1121-z
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Demography, baseline (Pre-bronchodilator) and maximal (Post-bronchodilator) pulmonary function tests for 105 Stratum 1 (healthy), 119 Stratum 2, 184 Stratum 3 and 103 Stratum 4 subjects
| Stratum 1 (Healthy) | Stratum 2 | Stratum 3 | Stratum 4 | ||
|---|---|---|---|---|---|
|
| |||||
| Age, yrs | 58.6 (10.5) | 65.1 (7.5) | 69.1 (6.4) | 65.2 (7.5) | < 0.0001 |
| BMI, kg/m2 | 28.4 (5.2) | 29.5 (4.8) | 28.4 (4.6) | 27.0 (4.7) | < 0.0001 |
| Sex, (Male/Female %) | 42/58 | 51.3/48.7 | 62.5/37.5 | 57.3/42.7 | = 0.02 |
| Race, Caucasian/ African American/ Other (%) | 62.3/26.1/ 11.6 | 81.5/12.6/ 5.9 | 88.0 /7.1/ 4.9 | 85.4 /9.7/ 4.9 | < 0.0001 |
|
| |||||
| FEV1% predicted | 98 (13) | 91 (14) | 67 (16) | 28 (8) | < 0.0001 |
| FVC % predicted | 98 (11) | 94 (13) | 91 (16) | 67 (15) | < 0.0001 |
| FEV1/FVC × 100 | 78 (6) | 74 (6) | 55 (9) | 32 (9) | < 0.0001 |
|
| |||||
| FEV1% predicted | 102 (12) | 97 (14) | 76 (15) | 34 (10) | < 0.0001 |
| FVC % predicted | 98 (11) | 95 (13) | 99 (15) | 76 (17) | < 0.0001 |
| FEV1/FVC × 100 | 81 (6) | 78 (5) | 57 (8) | 34 (9) | < 0.0001 |
Values expressed as mean (SD) or number (%). Kruskal-Wallis and chi-square tests were performed for continuous and categorical variables
aBaseline (Pre-bronchodilator) values with greater than six hours withhold of bronchodilators. bMaximal (Post-bronchodilator) values after six to eight puffs of albuterol
Fig. 1An expanded set of imaging-based metrics including emphysema percentage, tissue fraction at TLC and RV. a Inspirational image-based local structures: θ, Cr, WT*, and Dh*. b Expiration image-based global and lobar function: AirT%. c Inspiration image-based global and lobar function: Emph%. d Global structure:. e Registration-based global and lobar functions:.
Major imaging-based features selected by Wilk’s λ value of a stepwise forward variable selection method in four imaging-based clusters and healthy subjects (stratum 1)
| Variable | Region | Wilk’s | Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | Stratum 1 | |
|---|---|---|---|---|---|---|---|---|
| βtissueRV | Total | 0.286 | 0.240 (0.041) | 0.245 (0.041) | 0.172 (0.026) | 0.110 (0.020) | < 0.0001 | 0.264 (0.054) |
| Jacobian | Total | 0.145 | 2.16 (0.259) | 1.67 (0.200) | 1.63 (0.201) | 1.32 (0.147) | < 0.0001 | 2.11 (0.378) |
| Emph% | Total | 0.116 | 5.8 (0.058) | 2.4 (0.026) | 10.4 (0.073) | 25.0 (0.110) | < 0.0001 | 0.024 (0.028) |
| fSAD% | Total | 0.093 | 8.7 (0.065) | 7.5 (0.055) | 23.5 (0.086) | 36.8 (0.074) | < 0.0001 | 0.050 (0.052) |
| βtissueTLC | Total | 0.080 | 0.109 (0.015) | 0.142 (0.019) | 0.103 (0.014) | 0.081 (0.014) | < 0.0001 | 0.122 (0.03) |
Values expressed as mean (SD). Full names of each variable or region were described in Abbreviations used
Fig. 2A summary of imaging and clinical characteristics between clusters
Fig. 3a Percentage of emphysema (Emph%) for four clusters and the healthy control group (green). † P > 0.05 between clusters 1, 2, 3 and the healthy group. P < 0.05 between Cluster 4 and other groups for all pairwise comparisons b Percentage of small airway disease (fSAD%) for four clusters and the healthy control group (green). ‡ P < 0.05 for comparisons between four clusters 2, 3, 4 (red) and the healthy group for all pairwise comparison. P > 0.05 for between Cluster 1 and the healthy group
Segmental airway features at specific regions
| Variable | Region | Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | Healthy | |
|---|---|---|---|---|---|---|---|
|
| Trachea | 91.1 (12.3) | 93.0 (10.1) | 91.1 (12.8) | 86.5 (11.4) | < 0.001 | 91.8 (10.9) |
|
| sLUL | 0.961 (0.014) | 0.959 (0.015) | 0.956 (0.012) | 0.943 (0.021) | < 0.0001 | 0.958 (0.013) |
| WT* | sLUL | 0.571 (0.035) | 0.564 (0.034) | 0.546 (0.035) | 0.536 (0.042) | < 0.0001 | 0.561 (0.036) |
| sLUL | 0.273 (0.028) | 0.256 (0.029) | 0.236 (0.024) | 0.230 (0.033) | < 0.0001 | 0.264 (0.031) |
Cr, WT*, and Dh* were only presented at sLUL, but overall trends between clusters were consistent in different locations
Demography, baseline (pre-bronchodilator) and maximal (post-bronchodilator) PFTs, in four imaging-based clusters
| Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | ||
|---|---|---|---|---|---|
|
| |||||
| GOLD (%) (0/1/2/3/4) | 62/23/14/1/0 | 57/20/20/2/0 | 6/24/51/16/3 | 2/0/12/46/40 | < 0.0001 |
| Strata (%) (2/3/4) | 62/37/1 | 57/40/2 | 6/74/19 | 2/12/86 | < 0.0001 |
| BODE index | 0.28 (0.61) | 0.60 (1.12) | 1.31 (1.78) | 3.99 (2.00) | < 0.0001 |
| Sex (Female %) | 32 | 64 | 34 | 41 | 0.00015 |
| Race (White/African-American/Other) | 88/6/6 | 75/20/5 | 91/4/5 | 84/12/5 | 0.0088 |
| Age (yrs.) | 64.91 (7.11) | 66.59 (7.92) | 69.37 (5.94) | 65.67 (7.92) | < 0.0001 |
| BMI (kg/m2) | 28.67 (4.43) | 30.76 (4.55) | 28.49 (4.6) | 25.68 (4.44) | < 0.0001 |
|
| |||||
| FEV1% predicted | 88 (18) | 79 (16) | 59 (20) | 31 (15) | < 0.0001 |
| FVC % predicted | 97 (14) | 88 (14) | 85 (18) | 71 (19) | < 0.0001 |
| FEV1/FVC × 100 | 68 (10) | 68 (9) | 51 (11) | 32 (10) | < 0.0001 |
|
| |||||
| FEV1% predicted | 95 (17) | 86 (16) | 68 (19) | 37 (17) | < 0.0001 |
| FVC % predicted | 101 (14) | 91 (14) | 94 (17) | 80 (20) | < 0.0001 |
| FEV1/FVC × 100 | 72 (10) | 71 (9) | 53 (11) | 34 (12) | < 0.0001 |
Data presented as number (%) or mean (SD)
aPre-bronchodilator values
bPost-bronchodilator values after six to eight puffs of albuterol. Full names of each variable were described in Abbreviations used. BODE indexes for 24 subjects were not available
Associations of symptoms and disease histories with cluster membership
| Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | ||
|---|---|---|---|---|---|
|
| |||||
| Smoking pack-years at baseline | 48.09 (22.27) | 48.21 (25.3) | 57.64 (27.4) | 54.44 (22.9) | 0.001 |
| History of pulmonary/vascular condition (%) | 24 | 18 | 21 | 39 | 0.0056 |
| Chronic Bronchitis (%) | 10 | 18 | 19 | 31 | 0.005 |
| Emphysema (%) | 28 | 24 | 45 | 76 | < 0.0001 |
| COPD diagnosed at baseline (%) | 40 | 34 | 64 | 88 | < 0.0001 |
| Chronic bronchitis diagnosed at baseline (%) | 11 | 5 | 16 | 19 | 0.061 |
| Asthma (%) | 12 | 20 | 19 | 23 | 0.285 |
| Wheezing and whistling in chest (%) | 46 | 50 | 59 | 59 | 0.167 |
| Wheezing age (yrs.) (%) | 60 | 67 | 78 | 68 | 0.19 |
| Sleep Apnea at baseline (%) | 28 | 29 | 15 | 17 | 0.106 |
| Shortness of breath during sleep (%) | 6 | 17 | 7 | 17 | 0.012 |
| Coronary artery disease | 6 | 12 | 15 | 7 | 0.101 |
| Diabetes (%) | 12 | 19 | 11 | 14 | 0.452 |
| Heart attack (%) | 1 | 5 | 6 | 10 | 0.08 |
| Congestive heart failure (%) | 1 | 2 | 3 | 2 | 0.81 |
|
| |||||
| Father had COPD (%) | 15 | 14 | 22 | 33 | 0.006 |
| Mother had COPD (%) | 9 | 12 | 12 | 23 | 0.041 |
Characteristics of biomarkers in four imaging-based clusters
| Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | ||
|---|---|---|---|---|---|
|
| |||||
| RBC distribution width (%) | 13.69 (1.49) | 13.66 (1.62) | 13.77 (1.54) | 13.78 (1.57) | 0.953 |
| Total WBC count (N/μl) | 6203.8 (1595.18) | 6773.08 (1954.3) | 6907.27 (1721.5) | 7330.24 (2155.13) | 0.0005 |
| Neutrophils% (%) | 59.74 (8.48) | 61.17 (9.35) | 62.12 (8.32) | 63.5 (11.2) | 0.044 |
| Lymphocyte% (%) | 28.38 (7.98) | 27.28 (8.74) | 25.97 (7.14) | 23.9 (9.47) | 0.002 |
| Monocyte% (%) | 7.97 (2.43) | 7.72 (2.44) | 8.3 (2.55) | 8.06 (2.71) | 0.432 |
| Eosinophils% (%) | 3.29 (2.12) | 3.18 (1.98) | 2.85 (1.62) | 2.64 (1.73) | 0.071 |
| Basophils% (%) | 0.68 (0.41) | 0.59 (0.41) | 0.65 (0.52) | 0.57 (0.56) | 0.321 |
| Matrix metalloproteinase (MMP-3) (pg/mL) | 10.17 (8.1) | 8.41 (4.65) | 11.07 (6.12) | 12.43 (10.57) | 0.0082 |
|
| |||||
9.36 (6.19) | 10.73 (6.61) | 10.96 (6.38) | 17.06 (7.34) | < 0.0001 | |
|
| |||||
| Severeb | 0.08 (0.34) | 0.25 (1.11) | 0.23 (0.7) | 0.84 (1.61) | < 0.0001 |
| Totalc | 0.44 (0.96) | 0.81 (1.78) | 0.94 (1.52) | 2.56 (3.09) | < 0.0001 |
| Total at baselined | 0.16 (0.44) | 0.32 (0.87) | 0.21 (0.53) | 0.66 (0.92) | < 0.0001 |
|
| |||||
| 6-min walk distance (m) | 459.23 (84.5) | 431.4 (91.71) | 412.76 (113.09) | 338.5 (114.57) | < 0.0001 |
| Oxygen desaturation with 6-min walk (%) | 18 | 17 | 36 | 76 | < 0.0001 |
Kruskal-Wallis and chi-square tests were performed for continuous and categorical variables, respectively, and their P values were reported
aCAT score range from 0 to 40, with higher scores indicating greater severity symptoms
bTotal count of exacerbations requiring ED visit or hospitalization since entering the study
cTotal count of exacerbations since entering the study
dTotal Exacerbations for baseline
Associations of visual diagnostics (VD) and of emphysema subtypes with cluster membership
| Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | ||
|---|---|---|---|---|---|
|
| |||||
| Bronchiectasis (%) | 45 | 31 | 57 | 62 | 0.018 |
| Interstitial lung disease (ILD, %) | 25 | 34 | 30 | 10 | 0.030 |
| Lung nodule (%) | 65 | 68 | 73 | 61 | 0.476 |
| Ground glass opacities (GGO) | 93% | 100% | 95% | 60% | 0.023 |
| Reticular opacities | 93% | 93% | 100% | 80% | 0.309 |
| Honeycombing | 57% | 29% | 65% | 40% | 0.163 |
|
| |||||
| CLE | 7.8% | 16.1% | 10.8% | 6.1% | 0.481 |
| PSE | 9.8% | 12.9% | 0 | 0 | < 0.005 |
| PLE | 0 | 0 | 0 | 0 | NS |
| CLE + PSE | 82.4% | 67.7% | 85.1% | 65.3% | < 0.005 |
| CLE + PLE | 0 | 0 | 0 | 10.2% | < 0.005 |
| PSE + PLE | 0 | 0 | 0 | 0 | NS |
| CLE + PSE + PLE | 0 | 0 | 4.1% | 18.4% | < 0.0001 |
|
| |||||
| (ΔEmph% ≥ 1%) (Rapid-progressors) | |||||
| 25% | 11% | 58% | 68% | < 0.001 | |
Kruskal-Wallis and chi-square tests were performed for continuous and categorical variables, respectively, and their P values were reported
Kruskal-Wallis and chi-square tests were performed for continuous and categorical variables, respectively. Five hundred ninety-nine SPIROMICS subjects were used for progression index (169 former smokers were available)
CLE Centrilobular, PSE Paraseptal, PLE Panlobular emphysema
Comparison of major clinical and biomarkers between current and former smokers
| Current smokers | |||||
|---|---|---|---|---|---|
| Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | ||
| Total WBC count (N/μl) | 7153 (2291) | 7353 (2527) | 7110 (1954) | 7073 (2123) | 0.924 |
| Baseline CAT score | 13.17 (7.95) | 16.45 (9.54) | 13.78 (7.86) | 20.06 (7.86) | < 0.0001 |
| BMI (kg/m2) | 27.63 (4.7) | 31.1 (5.04) | 25.58 (4.76) | 23.65 (4.26) | < 0.0001 |
| Exacerbations | |||||
| Severe | 0.2 (0.6) | 0.44 (1.62) | 0.31 (0.82) | 1.25 (2.27) | < 0.0001 |
| Total | 0.49 (1.19) | 1.09 (3.39) | 0.92 (2.14) | 2.09 (2.91) | < 0.0001 |
| Total at baseline | 0.25 (0.68) | 0.58 (1.39) | 0.22 (0.63) | 0.62 (0.99) | 0.011 |
| Oxygen desaturation with 6-min walk (%) | 14 | 36 | 14 | 41 | < 0.0001 |
| Post-bronchodilator values (FEV1/FVC × 100) | 74 (9) | 68 (13) | 63 (11) | 44 (12) | < 0.0001 |
| Former smokers | |||||
| Total WBC count (N/μl) | 6204 (1595) | 6773 (1954) | 6907.27 (1722) | 7330.24 (2155) | 0.005 |
| Baseline CAT score | 9.36 (6.19) | 10.73 (6.61) | 10.96 (6.38) | 17.06 (7.33) | < 0.0001 |
| BMI (kg/m2) | 28.67 (4.43) | 30.76 (4.55) | 28.49 (4.60) | 25.68 (4.44) | < 0.0001 |
| Exacerbations | |||||
| Severe | 0.08 (0.34) | 0.25 (1.11) | 0.23 (0.70) | 0.84 (1.61) | < 0.0001 |
| Total | 0.44 (0.96) | 0.81 (1.78) | 0.94 (1.52) | 2.56 (3.09) | < 0.0001 |
| Total at baseline | 0.16 (0.44) | 0.32 (0.87) | 0.21 (0.53) | 0.66 (0.92) | < 0.0001 |
| Oxygen desaturation with 6-min walk (%) | 18 | 17 | 37 | 76 | < 0.0001 |
| Post-bronchodilator values (FEV1/FVC × 100) | 72 (10) | 71 (9) | 53 (11) | 34 (12) | < 0.0001 |
Kruskal-Wallis and chi-square tests were performed for continuous and categorical variables, respectively, and their P values were reported
Fig. 4Kernel density estimation (KDE) plots with contour labels based on Emph% and fSAD% for current and former smokers